EXEL biotech catalysts & pipeline

EXELIXIS INC · Data as of 2026-10-25

Upcoming catalysts

somatostatin receptor subtype 2 agonist program — IND submission

in 2026

We also expect to progress a development candidate from our somatostatin receptor subtype 2 agonist program toward a potential investigational new drug (IND) filing in 2026.

Source filing

XB773 — IND submission

in 2026

We also expect to progress XB773, an ADC targeting the tumor antigen DLL3 toward a potential IND filing in 2026.

Source filing

zanzalintinib — IND submission

in 2026

We also expect to progress a development candidate from our somatostatin receptor subtype 2 agonist program toward a potential investigational new drug (IND) filing in 2026.

Source filing

zanzalintinib — Topline data

H2 2026

In May 2026, Exelixis announced that the company expects topline results from the STELLAR-304 trial in the second half of 2026, depending on event rates.

Source filing

zanzalintinib — PDUFA

Dec 3

The FDA assigned a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.

Source filing

zanzalintinib — PDUFA

Mar 3

The updated Prescription Drug User Fee Act action date is March 3, 2027.

Source filing

Explore the free biotech catalyst calendar